Ken Rollins


I am an extension of my clients, serving as an advisor at critical inflection points as my clients grow and succeed.

Ken Rollins represents emerging and late stage private companies and public companies in a wide range of corporate and securities matters, including private financings, public offerings, M&A, tender offers, strategic collaborations, commercial agreements, corporate governance matters and employment and compensation arrangements. He also advises venture capital firms in connection with financings and other transactions. Over the past five years, he has represented companies and venture capitalists in more than 50 private financings and helped clients achieve an aggregate of $5+ billion in successful exit transactions.

Download full bio 


  • Design Therapeutics $125 million Series B Financing and $240 million IPO 

  • Silverback Therapeutics: $242 million Initial Public Offering 

  • VelosBio Agrees to Sell to Merck for $2.75 Billion 

  • Synthorx: $63 Million Series C Financing 

  • Auspex Pharma Acquired by Teva for $3.5 Billion 

  • View all


  • University of Virginia School of Law
    JD, 2002

  • Southern Utah University
    BA, Accounting
    Valedictorian, 1998

Admissions & Credentials